Online inquiry

IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14928MR)

This product GTTS-WQ14928MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets stx2 A-subunit gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq WP_001367518.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8VLD2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14928MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15386MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ1116MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11606MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ2552MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ1959MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ13446MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ13976MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ12456MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW